Newsfeeds - Spark Newswire

1 minute read

Ault Global Founder Tweets ‘$DPW has its fully reported position in $ALZN we have not sold any shares and would be required to report that if we did. We look forward to seeing the top line data for AL001…’

By Benzinga Newsdesk

Today, 4:20 PM

https://twitter.com/ToddAultIII/status/1468244135178125323?s=20

ALZN

6 minute read

76 Biggest Movers From Yesterday

By Lisa Levin

Today, 4:20 PM

Gainers Expensify, Inc. (NASDAQ: EXFY) jumped 52.1% to settle at $41.06 on Wednesday after the company priced its IPO at $27 per share.

AADI

1 minute read

Alzamend Neuro Reports In Form4 Filing Ault Milton Buys 145K Shares

By Benzinga Newsdesk

Today, 4:20 PM

-SEC Filing

ALZN

7 minute read

92 Biggest Movers From Friday

By Lisa Levin

Today, 4:20 PM

Gainers

AAOI

5 minute read

64 Stocks Moving In Friday’s Mid-Day Session

By Lisa Levin

Today, 4:20 PM

Gainers Mainz Biomed B.V. (NASDAQ: MYNZ) shares climbed 198.4% to $14.92. Mainz Biomed priced its initial public offering of 2 million ordinary shares at $5, the middle of the estimated price range of $4-$6, for raising gross proceeds of $10 million.

AAOI

5 minute read

54 Biggest Movers From Friday

By Lisa Levin

Today, 4:20 PM

Gainers

ADGI

3 minute read

35 Stocks Moving In Friday’s Mid-Day Session

By Lisa Levin

Today, 4:20 PM

Gainers Biomerica, Inc. (NASDAQ: BMRA) shares climbed 38.3% to $6.23. Biomerica entered into a Supplier Agreement with Walmart to sell its EZ Detect colorectal disease screening test within the Walmart retail system.

ADGI

13 minute read

Benzinga’s Top Ratings Upgrades, Downgrades For October 1, 2021

By Benzinga Insights

Today, 4:20 PM

AADI

5 minute read

The Daily Biotech Pulse: Merck Rallies On Antiviral Pill Data, Gilead Files For Yescarta Label Expansion, Exscientia IPO

By Shanthi Rexaline

Today, 4:20 PM

Here's a roundup of top developments in the biotech space over the last 24 hours. Click here for accessing Benzinga's FDA Calendar Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 30)

ADMA

1 minute read

Ascendiant Capital Initiates Coverage On Alzamend Neuro with Buy Rating, Announces Price Target of $8

By Benzinga Newsdesk

Today, 4:20 PM

Ascendiant Capital analyst Edward Woo initiates coverage on Alzamend Neuro (NASDAQ:ALZN) with a Buy rating and announces Price Target of $8.

ALZN